Results 51 to 60 of about 958,890 (240)

IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.

open access: yesCancer Discovery, 2018
Pancreatic ductal adenocarcinoma (PDAC) is poorly responsive to therapies and histologically contains a paucity of neoplastic cells embedded within a dense desmoplastic stroma. Within the stroma, cancer-associated fibroblasts (CAF) secrete tropic factors
Giulia Biffi   +7 more
semanticscholar   +1 more source

Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance

open access: yesNature Cancer, 2022
Emerging evidence indicates that various cancers can gain resistance to targeted therapies by acquiring lineage plasticity. Although various genomic and transcriptomic aberrations correlate with lineage plasticity, the molecular mechanisms enabling the ...
S. Deng   +25 more
semanticscholar   +1 more source

Effects of CaO, Al2O3 and MgO on liquidus temperatures of copper smelting and converting slags under controlled oxygen partial pressures [PDF]

open access: yesJournal of Mining and Metallurgy. Section B: Metallurgy, 2013
Phase equilibria of silicate slags relevant to the copper smelting/converting operations have been experimentally studied over a wide range of slag compositions, temperatures and atmospheric conditions.
Zhao B., Hayes P., Jak E.
doaj   +1 more source

Detecting Transient Trapping from a Single Trajectory: A Structural Approach

open access: yesEntropy, 2021
In this article, we introduce a new method to detect transient trapping events within a single particle trajectory, thus allowing the explicit accounting of changes in the particle’s dynamics over time.
Yann Lanoiselée   +3 more
doaj   +1 more source

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

open access: yesScientific Reports, 2022
Increasing number of Janus kinase (JAK) inhibitors have been approved for chronic haematopoietic neoplasms and inflammatory/autoimmune diseases.
L. Hoisnard   +13 more
semanticscholar   +1 more source

Evaluating Cluster-Level Factor Models with lavaan and Mplus

open access: yesPsych, 2021
Background: Researchers frequently use the responses of individuals in clusters to measure cluster-level constructs. Examples are the use of student evaluations to measure teaching quality, or the use of employee ratings of organizational climate.
Suzanne Jak   +2 more
doaj   +1 more source

Regulation of pancreatic cancer aggressiveness by stromal stiffening [PDF]

open access: yes, 2016
No abstract ...
A Neesse   +13 more
core   +1 more source

Exploring the JAK/STAT Signaling Pathway in Hepatocellular Carcinoma: Unraveling Signaling Complexity and Therapeutic Implications

open access: yesInternational Journal of Molecular Sciences, 2023
Hepatocellular Carcinoma (HCC) continues to pose a substantial global health challenge due to its high incidence and limited therapeutic options. In recent years, the Janus Kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) pathway ...
H. Park   +4 more
semanticscholar   +1 more source

Inhibition of IL‐6‐JAK/Stat3 signaling in castration‐resistant prostate cancer cells enhances the NK cell‐mediated cytotoxicity via alteration of PD‐L1/NKG2D ligand levels

open access: yesMolecular Oncology, Volume 12, Issue 3, Page 269-286, March 2018., 2018
IL‐6 signaling, through downstream JAK/Stat3 signaling, plays a significant role in rendering castration‐resistant prostate cancer (CRPC) cells resistant to NK cell cytotoxicity by lowering the programmed death receptor ligand 1 level while increasing the NK group 2D ligand levels.
LiJun Xu   +9 more
wiley   +1 more source

Research progress on tofacitinib in the treatment of chronic actinic dermatitis

open access: yesPifu-xingbing zhenliaoxue zazhi
Chronic actinic dermatitis (CAD) is a group of immune-mediated diseases characterized by photosensitivity. Tofacitinib, a Janus kinase (JAK) 1/3 inhibitor, is currently the most extensively reported and widely used JAK inhibitor for the treatment of CAD.
WU Hui   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy